Latest stories on MDGL
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Yahoo Top63 · neutralgeneral
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
The Motley Fool63 · neutralgeneral
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
StockTitan56 · neutralgeneral
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
The Motley Fool57 · neutralgeneral
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Madrigal Pharmaceuticals Adds Renowned Leader to Board
TipRanks65 · bullishgeneral
MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-K
SEC 8-K50 · neutralgeneral
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Business Insider55 · neutralgeneral
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Seeking Alpha55 · neutralgeneral
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
StockTitan50 · neutralgeneral
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach
Seeking Alpha58 · neutralproduct/pr
Wolfe Research upgrades Madrigal Pharmaceuticals stock rating on Q2 beat
Investing.com Analyst Ratings63 · neutralanalyst
Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)
Seeking Alpha63 · neutralearnings
H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Barclays lowers Madrigal Pharmaceuticals stock price target to $962
Investing.com Analyst Ratings34 · bearishanalyst
Madrigal outlines 2027 F4c outcomes readout while reinforcing mid- to high 30s 2026 gross-to-net outlook
Seeking Alpha63 · neutralproduct/pr
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Seeking Alpha56 · neutralearnings
Madrigal’s Q2 2026 Results Highlight Surging Rezdiffra Adoption, Expanded Patents, and Pipeline Progress
July 30, 2026
MarketChameleon73 · bullishearnings
Madrigal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Madrigal Pharmaceuticals GAAP EPS of -$1.99 beats by $0.65, revenue of $364.3M beats by $11.13M
Seeking Alpha68 · bullishearnings
MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-K
SEC 8-K50 · neutralgeneral
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Business Insider63 · neutralearnings